New Developments Show a Promising Future for Ovarian Cancer Treatments

For their trial, researchers studied the effects of Rubraca on a sample of 564 different women with ovarian cancer. Within the sample, 196 of the women had a BRCA mutation. Researchers compared the effects of Rubraca in two different groups, patients with a BRCA mutation and patients with some other kind of genetic mutation. Among the group that had a BRCA mutation, the patients that were given Rubraca had an average progression free survival of 26.8 months, compared to 5.4 progression free months in the placebo group. The results within the BRCA group were the most drastic, however, researchers did also find success within the second group.

Patients with a genetic mutation other than a BRCA mutation who were given Rubraca had an average of 8.2 progression free months of survival, which is compared to 5.3 months in the group that received the placebo. In addition to studying the two groups separately, researchers also analyzed the data as a whole. When viewed as one collective group, the patients given Rubraca had 13.7 months of progression free survival. The team concluded that whether a woman had ovarian cancer due to a BRCA mutation or some other genetic deformity, Rubraca would assist in the treatment process and deter the progression of the disease.